Glofitamab for diffuse large B cell lymphoma

ZHENG Li; ZHANG Kaihua; SUN Xuelin

doi:10.6039/j.issn.1001-0408.2023.24.20

您当前的位置：

首页 >

文章列表页 >

Glofitamab for diffuse large B cell lymphoma

更新时间：2023-12-22

- Glofitamab for diffuse large B cell lymphoma
- ZHONGGUO YAOFANG Vol. 34, Issue 24, Pages: 3064-3067(2023)
- 作者机构：
  
  1.中国航天科工集团七三一医院药学部，北京　100074
  2.中国航天科工集团七三一医院胸外科，北京　100074
  3.北京医院药学部，北京　100730
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.24.20
  CLC： R979.1
- Published：30 December 2023，
  
  Received：21 July 2023，
  
  Revised：01 November 2023，
扫描看全文
郑丽,张凯华,孙雪林.弥漫大B细胞淋巴瘤治疗新药格菲妥单抗 ^Δ[J].中国药房,2023,34(24):3064-3067.

ZHENG Li,ZHANG Kaihua,SUN Xuelin.Glofitamab for diffuse large B cell lymphoma[J].ZHONGGUO YAOFANG,2023,34(24):3064-3067.
郑丽,张凯华,孙雪林.弥漫大B细胞淋巴瘤治疗新药格菲妥单抗 ^Δ[J].中国药房,2023,34(24):3064-3067. DOI： 10.6039/j.issn.1001-0408.2023.24.20.

ZHENG Li,ZHANG Kaihua,SUN Xuelin.Glofitamab for diffuse large B cell lymphoma[J].ZHONGGUO YAOFANG,2023,34(24):3064-3067. DOI： 10.6039/j.issn.1001-0408.2023.24.20.

摘要

弥漫大B细胞淋巴瘤（DLBCL）是一种来源于成熟B细胞的恶性肿瘤，目前其临床治疗以化学治疗为主，但仍有部分患者会在治疗后复发或进展为难治性DLBCL。2023年6月15日，美国FDA批准抗CD3/CD20双特异性单克隆抗体格菲妥单抗上市，为既往接受过二线或二线以上系统治疗后复发或进展为难治性DLBCL的患者提供了新的治疗方案。本文对格菲妥单抗的药理作用、临床研究、安全性及用法用量等进行了简要概述。格菲妥单抗主要通过促进T细胞的活化和增殖，激活T细胞释放肿瘤细胞杀伤蛋白，进而介导B细胞的裂解而发挥治疗DLBCL的作用。临床研究显示，格菲妥单抗对复发或难治性DLBCL具有较好的完全缓解率和客观缓解率，其常见不良反应包括轻/中度细胞因子释放综合征、肌肉骨骼疼痛、皮疹和疲劳，未见明显的药物相互作用。

Abstract

Diffuse large B cell lymphoma （DLBCL） is a malignant tumor derived from mature B cells. Currently， chemotherapy is still the main clinical treatment. However， some patients experience recurrence or refractory conditions after treatment. On June 15， 2023， the FDA approved the marketing of glofitamab， a CD3/CD20 bispecific monoclonal antibody， to provide the new treatment plan for patients with recurrent or refractory DLBCL after receiving 2-line or above systemic treatment. This article reviews pharmacological effects， clinical studies， safety， usage and dosage of glofitamab. Glofitamab mainly plays a therapeutic role in DLBCL by promoting the activation and proliferation of T cells，activating T cells to release tumor cell-killing proteins， and mediating the lysis of B cells. Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL. Common adverse reactions caused by glofitamab include mild/moderate cytokine release syndrome， musculoskeletal pain， rash， fatigue， and so on，without significant drug interactions.

关键词

格菲妥单抗弥漫大B细胞淋巴瘤抗CD3/CD20双特异性单克隆抗体药理作用临床研究安全性

Keywords

diffuse large B cell lymphomaCD3/CD20 bispecific monoclonal antibodypharmacological effectsclinical studysafety

references

DUNLEAVY K，ERDMANN T，LENZ G. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma[J]. Cancer Treat Rev，2018，65：41-46.

佟丹江. 弥漫大B细胞淋巴瘤的流行病学分析[J]. 中国现代药物应用，2016，10（8）：46-47.

TONG D J. Epidemiological analysis of diffuse large B-cell lymphoma[J]. Chin J Mod Drug Appl，2016，10（8）：46-47.

SEHN L H，GASCOYNE R D. Diffuse large B-cell lymphoma：optimizing outcome in the context of clinical and biologic heterogeneity[J]. Blood，2015，125（1）：22-32.

GOLDFINGER M，COOPER D L. lenalidomide in DLBCL：are we past the cell of origin?[J]. Clin Adv Hematol Oncol，2021，19（5）：320-325.

MINSON A，DICKINSON M. Glofitamab CD20-TCB bispecific antibody[J]. Leuk Lymphoma，2021，62（13）：3098-3108.

SUROWKA M，SCHAEFER W，KLEIN C. Ten years in the making：application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins[J]. mAbs，2021，13（1）：1967714.

CREMASCO F，MENIETTI E，SPEZIALE D，et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model[J]. PLoS One，2021，16（1）：e0241091.

FDA. Glofitamab-gxbm（Columvi） prescribing information[EB/OL].（2023-06-15）[2023-07-21]. https：//www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf.

DICKINSON M J，CARLO-STELLA C，MORSCHHAUSER F，et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med，2022，387（24）：2220-2231.

SONG Y Q，ZHANG H L，HUANG H Q，et al. Glo-fitamab monotherapy demonstrates high complete response rates and manageable safety in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma and ≥2 prior therapies[J]. Blood，2022，140（supplement 1）：12050-12051.

HUTCHINGS M，SUREDA A，TEROL M J，et al. Glofi-tamab（glofit）in combination with polatuzumab vedotin（pola）：phase Ⅰb/Ⅱ preliminary data support manageable safety and encouraging efficacy in relapsed/refractory（R/R）diffuse large B-cell lymphoma（DLBCL）[J]. Blood，2021，138（Supplement 1）：525.

TOPP M S，TANI M，DICKINSON M，et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma（DLBCL）：results from a phase Ⅰb study[J]. Blood，2022，140（Supplement 1）：1775-1777.

GUST J，HAY K A，HANAFI L A，et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J]. Cancer Discov， 2017，7（12）：1404-1419.

MAUDE S L，FREY N，SHAW P A，et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med， 2014，371（16）：1507-1517.

BACAC M，COLOMBETTI S，HERTER S，et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies[J]. Clin Cancer Res，2018，24（19）：4785-4797.

SANCHEZ-PAULETE A R，LABIANO S，RODRIGUEZ-RUIZ M E，et al. Deciphering CD137（4-1BB）signaling in T-cell costimulation for translation into successful cancer immunotherapy[J]. Eur J Immunol，2016，46（3）：513-522.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical observation of tofacitinib combined with hydroxychloroquine in the treatment of refractory rheumatoid arthritis

Efficacy and safety comparison of lacosamide and carbamazepine in the treatment of adult patients with newly diagnosed epilepsy

Meta-analysis of efficacy and safety of sedative therapy with midazolam and dexmedetomidine/propofol in critically ill patients undergoing mechanical ventilation

Efficacy and safety of tyrosine kinase inhibitors in the treatment of HER2-positive breast cancer： a meta-analysis

Efficacy and safety of domestic Paliperidone extended-release tablets in the treatment of stable schizophrenia

Related Author

WANG Mingjie

XU Fengjin

ZHANG Yan

XUE Yan

GUO Xiaqing

LI Guofei

SUN Yuhua

ZHENG Donglin

Related Institution

Dept. of General Medicine， Hengshui Municipal People’s Hospital

College of Clinical Medicine， Hebei Medical University

Dept. of Rheumatology and Immunology， Hengshui Municipal People’s Hospital

First Ward， Dept. of Neurology， Huaihe Hospital of Henan University

Dept. of Intensive Care Medicine， the Fourth Hospital of Hebei Medical University

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰